<DOC>
	<DOCNO>NCT00220506</DOCNO>
	<brief_summary>To determine whether therapy Modafinal ( Provigil ) safe effective fatigue MS Patients</brief_summary>
	<brief_title>Fatigue Treatment Using Provigil</brief_title>
	<detailed_description>Multiple sclerosis fatigue Fatigue one common symptom multiple sclerosis ( MS ) , occur 30 % -80 % patient many fatigue disable symptom ( 1 ) . Definition fatigue accord MS Council Clinical Practice Guidelines follow : “ A subjective lack physical and/or mental energy perceive individual caregiver interfere usual desired activity ” . As fatigue subjective non-specific symptom , easily confuse either weakness depress mood , common MS , follow characteristic define well diagnose MS-associated fatigue : - MS-related fatigue generally occur daily basis . - It tend worsen day progress . - It tend aggravated heat humidity . - It directly correlate either depression degree physical impairment . - It may occur first thing morning even patient restful full night 's sleep . The current medication use treatment MS-associated fatigue amantadine hydrochloride pemoline useful , patient . In multicenter trial ( 2 ) find 100 mg amantadine twice daily significantly improve fatigue . Pemoline placebo-controlled trial ( 3 ) fail show significant effect fatigue MS patient poorly tolerate side effect occur 25 % patient . A third trial ( 4 ) compare pemoline amantadine placebo , show positive trend pemoline , amantadine benefit placebo fatigue measure . There also mark placebo effect trial , approximately half patient report improvement fatigue matter treatment ( pemoline , amantadine placebo ) take . In current study proposal intend evaluate effect Provigil MS-associated fatigue . The possibility add-on drug affect fatigue MS importance , fatigue significant impact activity daily live , interfere work , family life social activity . 1.2 . The fatigue scale name “ Fatigue Impact Scale ” The awareness impact fatigue patient ’ quality life ( QOL ) need evaluate effect different therapy parameter result development validation different questionnaire measurement fatigue , i.e. , Fatigue Impact Scale ( FIS ) , show measure , fatigue treatment effect fatigue ( 6-9 ) . The FIS reliable validate 40-items questionnaire capable select treatment effect . It make 3 sub-scales : physical , cognitive social . Each question score 0-4 , allow total score 160 . High score indicate high impairment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>The patient diagnose clinically definite MS ( Posner criterion ) . EDSS screening : 0 5.5 , inclusive . Positive Fatigue impact scale 40 point . Age 1855 year . Cooperating patient , capable comply trial procedure ( i.e . FIS , QOL , etc… ) . Patient sign write informed consent . Women childbearing potential must use effective birth control method study . Life threaten and/or unstable clinical condition opinion investigator might compromise trial completion A relapse last 30 day prior study . Systemic steroid therapy within 30 day Known hypersensitivity intolerance , Provigil relate substance component formulation . Sleep apnea Narcolepsy Participation experimental drug trial last 30 day prior trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>provigil</keyword>
	<keyword>fatigue</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>cognition</keyword>
</DOC>